ChromaDex Launches Tru Niagen Immune
Tru Niagen® Immune is the first-ever immune health supplement with a targeted NAD+ boost for the optimal maintenance and function of aging cells
ChromaDex Corp. (NASDAQ:CDXC) today announced the company's
ChromaDex Announces Issuance Of Additional New US Continuation Patent
ChromaDex Corp. (NASDAQ:CDXC) today announced that it was granted an additional continuation patent, U.S. Patent No. 11,274,117, adding to its global patent portfolio surrounding nicotinamide riboside (NR) and other
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday's session, 454 stocks hit new 52-week lows.
B. Riley Securities Maintains Buy on ChromaDex, Lowers Price Target to $8
B. Riley Securities analyst Jeff Van Sinderen maintains ChromaDex (NASDAQ:CDXC) with a Buy and lowers the price target from $16 to $8.
Earnings Scheduled For March 9, 2022
Companies Reporting Before The Bell
• REV Group (NYSE:REVG) is expected to report quarterly earnings at $0.11 per share on revenue of $529.44 million.
ChromaDex Announces Issuance Of New US Continuation Patent
Newly granted continuation patent provides additional intellectual property protection for ChromaDex’s Niagen® (patented nicotinamide riboside) ingredient
LOS ANGELES--(BUSINESS WIRE)-- ChromaDex Corp.
ChromaDex Shares Gain On Niagen Supply Pact With US-Based Provider Of Dietary Supplements
ChromaDex Corp (NASDAQ: CDXC) has
Stocks That Hit 52-Week Lows On Friday
During Friday's session, 445 companies made new 52-week lows.